Earnings summaries and quarterly performance for CareDx.
Executive leadership at CareDx.
Board of directors at CareDx.
AT
Arthur Torres
Detailed
Director
BR
Bryan Riggsbee
Detailed
Director
CC
Christine Cournoyer
Detailed
Director
FC
Fred Cohen
Detailed
Director
GB
George Bickerstaff III
Detailed
Director
HV
Hannah Valantine
Detailed
Director
MG
Michael Goldberg
Detailed
Chairman of the Board of Directors
PM
Peter Maag
Detailed
Director
SG
Suresh Gunasekaran
Detailed
Director
Research analysts who have asked questions during CareDx earnings calls.
Mark Massaro
BTIG, LLC
4 questions for CDNA
Also covers: ADPT, AKYA, BLLN +19 more
Brandon Couillard
Wells Fargo & Company
3 questions for CDNA
Also covers: A, AVTR, BIO +10 more
MC
Mason Carrico
Stephens Inc.
3 questions for CDNA
Also covers: AKYA, CSTL, CTKB +13 more
Tycho Peterson
Jefferies
3 questions for CDNA
Also covers: A, AVTR, BIO +22 more
Thomas DeBourcy
Nephron Research
2 questions for CDNA
Also covers: NEOG, QTRX, TWST +2 more
William Bonello
Craig-Hallum Capital Group
2 questions for CDNA
Also covers: BDSX, CERS, EXAS +6 more
YC
Yi Chen
H.C. Wainwright & Co.
2 questions for CDNA
Also covers: ANGO, APDN, BLFS +22 more
Andrew Cooper
Raymond James
1 question for CDNA
Also covers: AZTA, CTKB, EXAS +12 more
Eduardo Martinez
H.C. Wainwright & Co.
1 question for CDNA
Also covers: TTOO
NC
Noah Colby
Jefferies
1 question for CDNA
PK
Prashant Kota
Goldman Sachs
1 question for CDNA
Also covers: MYGN, NEO
Tom DeBourcy
Nephron Research LLC
1 question for CDNA
Also covers: NEOG, RGEN, TECH +2 more
Recent press releases and 8-K filings for CDNA.
CareDx Announces Preliminary Q4 and Full Year 2025 Financial Results
CDNA
Earnings
Share Buyback
Revenue Acceleration/Inflection
- CareDx, Inc. reported preliminary, unaudited fourth quarter 2025 revenue of approximately $108 million, representing a 25% increase year-over-year.
- For the full year 2025, preliminary revenue was approximately $380 million, an increase of 14% year-over-year.
- The company executed a share repurchase of $12 million during Q4 2025, acquiring 773,000 shares at an average price of $15.79 per share, contributing to a total of $88 million in share repurchases for the full year 2025.
- As of December 31, 2025, cash, cash equivalents and marketable securities were approximately $200 million.
Jan 12, 2026, 12:08 PM
CareDx Announces Preliminary Q4 and Full Year 2025 Financial Results
CDNA
Earnings
Guidance Update
Share Buyback
- CareDx reported preliminary Fourth Quarter 2025 revenue of approximately $108 million, representing a 25% increase year-over-year.
- For the full year 2025, preliminary revenue was approximately $380 million, an increase of 14% year-over-year.
- The company's testing services revenue for Q4 2025 was approximately $78 million (up 23% year-over-year) and $274 million for the full year 2025 (up 10% year-over-year).
- CareDx had cash, cash equivalents and marketable securities of approximately $200 million as of December 31, 2025.
- The company executed share repurchases totaling $12 million (773,000 shares at an average price of $15.79) during Q4 2025 and $88 million (5.8 million shares at an average price of $15.16) for the full year 2025.
Jan 12, 2026, 12:05 PM
CareDx settles shareholder derivative lawsuit with corporate governance reforms
CDNA
Legal Proceedings
Board Change
- CareDx, Inc. has entered into a Stipulation and Agreement of Compromise, Settlement, and Release to resolve a shareholder derivative action (Case No. 3:25-cv-02036-TLT) and a related action (Case No. 2024-0282-NAC).
- The lawsuit alleged that individual defendants caused the company to issue materially false and misleading statements regarding testing services and engaged in improper schemes to inflate testing services revenue, breaching fiduciary duties and failing to maintain adequate oversight and internal controls.
- As part of the settlement, CareDx will implement Corporate Governance Reforms for a period of not less than four years.
- These reforms include Audit Committee enhancements, the creation of a management-level Disclosure Committee, and an independent compliance assessment by outside counsel by the end of the first fiscal quarter of 2026, with a budget of $250,000 for the assessment and an annual budget of not less than $250,000 for fiscal years 2027 and 2028 for implementation and monitoring.
- Individual stockholders will not receive any direct payment from this settlement.
Dec 18, 2025, 10:00 PM
CareDx Discusses Q3 Performance, Strategic Initiatives, and 2026 Outlook at Piper Sandler Conference
CDNA
Product Launch
Share Buyback
Guidance Update
- CareDx reported strong Q3 2025 growth, with Testing Services up nearly 19% year-over-year, Patient and Digital Services up 30%, and Lab Products up 22%.
- The company achieved record cash collections in Q3 2025, collecting over 120% of revenue in cash, and expects stability in revenue cycle management by mid-2026. They also went live with two Epic Aura integrations, with three more planned by year-end 2025, aiming for 50% of volume by the end of 2026.
- CareDx generated $35 million in cash last quarter and repurchased 9% of shares outstanding in 2025, prioritizing buybacks due to perceived undervaluation. The long-range plan targets a 20% EBITDA margin.
- Recent product launches include AlloSure Heart for pediatric patients, AlloSure for simultaneous pancreas and kidney transplants, HistoMap, and AlloSure Plus. The AlloHome trial completed its last patient visit, with full data expected in Q1 2026 and commercial launch in H2 2026 or early 2027.
- The draft Local Coverage Determination (LCD) proposal, which could create a $15 million headwind to revenue if finalized as written, is expected to be finalized in H1 2026, with the company anticipating modifications to testing frequency limits.
Dec 3, 2025, 9:30 PM
CareDx Discusses Q3 2025 Performance and Future Initiatives
CDNA
Product Launch
Share Buyback
New Projects/Investments
- CareDx reported strong Q3 2025 growth, with Testing Services up nearly 19% year over year, Patient and Digital Services growing by 30%, and Lab Products increasing by 22%.
- The company achieved record cash collections in Q3 2025 through revenue cycle management improvements and initiated Epic Aura integrations, with two sites live and a target of 50% of volume by the end of 2026.
- CareDx generated $35 million in cash in Q3 2025 and repurchased 9% of shares outstanding this year, with a capital allocation strategy focused on reducing share count and targeting a 20% EBITDA margin.
- Key product developments include the launch of HistoMap and AlloSure Plus in 2025, with commercial launches for AlloHome anticipated in the back half of 2026 or early 2027, and HistoMap Kidney billing later in 2026.
- Management discussed the draft LCD proposal, noting it affirmed coverage for surveillance testing but could create a $15 million headwind to revenue on a full-year basis if finalized as currently written, with finalization expected in the first half of 2026.
Dec 3, 2025, 9:30 PM
CareDx Discusses Q3 Performance, Strategic Initiatives, and Pipeline
CDNA
Product Launch
Share Buyback
New Projects/Investments
- CareDx reported a strong third quarter with Testing Services up nearly 19% year over year, Patient and Digital Services growing by 30%, and Lab Products up 22%.
- The company achieved record cash collections in Q3, collecting over 120% of its revenue in cash, and has implemented Epic Aura at two sites, with a goal to reach 50% of its volume through Epic Aura by the end of 2026.
- CareDx repurchased 9% of its shares outstanding in 2025, and its capital allocation strategy for 2026 prioritizes further share buybacks due to the perceived undervaluation of its stock.
- Key product developments include the publication of AlloSure 3, demonstrating the prognostic value of HeartCare, and plans to launch AlloHome commercially in H2 2026 or early 2027 and HistoMap Kidney for commercial billing later in 2026.
- A draft Local Coverage Determination (LCD) proposal, if finalized as written, could result in a $15 million headwind to revenue on a full-year basis, with finalization anticipated in H1 2026.
Dec 3, 2025, 9:30 PM
CareDx Reports Strong Q3 Performance and Outlines Strategic Growth Initiatives
CDNA
Revenue Acceleration/Inflection
Guidance Update
Share Buyback
- CareDx reported a strong third quarter, achieving 21% top-line revenue growth and 13% growth in testing services volume, with approximately 15% adjusted EBITDA.
- The company maintains a robust financial position with approximately $200 million in cash and no debt, and has repurchased nearly 10% of its stock year-to-date.
- Management is focused on improving revenue cycle management, aiming for an average selling price (ASP) of over $2,000 within three years, and expects tailwinds from the IOTA program to boost kidney volumes in 2026.
- CareDx anticipates a potential $15 million headwind if the draft Local Coverage Determination (LCD) policy is implemented as written, primarily due to proposed limitations on testing frequency.
- Strategic growth areas include expanding into cell therapy with AlloHeme, with full trial results expected in February 2026, and increasing Epic integrations, targeting 50% of volume through Epic by the end of next year.
Nov 20, 2025, 2:00 PM
CareDx Reports Strong Q3 Results and Discusses Growth Drivers
CDNA
Revenue Acceleration/Inflection
Share Buyback
New Projects/Investments
- CareDx reported a strong third quarter with 21% top-line revenue growth and 13% growth in testing services volume, achieving approximately 15% adjusted EBITDA. The company maintains a robust balance sheet with approximately $200 million in cash and no debt.
- The company has repurchased nearly 10% of its stock year-to-date, reflecting management's view that the stock is undervalued.
- Management anticipates the organ transplant market will return to a 5% CAGR over the next two years, with the IOTA program expected to boost kidney volumes by 2026.
- Significant progress in revenue cycle management is expected to improve average selling price (ASP), with $4 million-$6 million in Q4 revenue from prior period collections and an internal goal of over $2,000 ASP within three years. A new CPT code has also been secured for the product.
- CareDx is expanding into cell therapy, with full results for its AlloHeme trial anticipated in February 2026, representing a natural extension of its existing business.
Nov 20, 2025, 2:00 PM
CareDx Reports Strong Q3 Growth and Strategic Progress
CDNA
Revenue Acceleration/Inflection
Share Buyback
Guidance Update
- CareDx reported strong Q3 performance with 21% top-line revenue growth, 13% growth in testing services volume, and approximately 15% adjusted EBITDA.
- The company maintains a robust financial position with approximately $200 million in cash and no debt, and has repurchased nearly 10% of its stock year-to-date.
- Management is optimistic about the 3% average selling price (ASP) outlook, driven by successful revenue cycle management (RCM) initiatives, including a 200% increase in appeal volume and record cash collections in October.
- Strategic initiatives include securing a CPT code for AlloSure and targeting 10% of testing volume through Epic by year-end, with an expected 10% volume increase post-integration.
- While a potential $15 million headwind is anticipated if the draft LCD is finalized as written, the company notes that the commercial market does not impose similar testing limits.
Nov 20, 2025, 2:00 PM
CareDx Reports Strong Q3 2025 Results and Raises Full-Year Guidance
CDNA
Earnings
Guidance Update
Share Buyback
- CareDx reported strong Q3 2025 financial results, with total revenue of $100.1 million, a 21% year-over-year increase, and Adjusted EBITDA of $15.3 million, more than double Q3 last year.
- The company raised its full-year 2025 guidance for revenue to $372-$376 million and Adjusted EBITDA to $35-$39 million, reflecting strong Q3 performance.
- Operational efficiencies from Revenue Cycle Management led to significant improvements, including a 1,300 basis point reduction in claims rejection rate and DSOs improving from 71 to 44 days.
- CareDx repurchased an additional two million shares during the quarter at an average price of $12.87, bringing year-to-date repurchases to approximately 9% of shares outstanding.
Nov 4, 2025, 9:30 PM
Quarterly earnings call transcripts for CareDx.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more